Meeting
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
Authors
Yu Fujiwara
Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY
Yu Fujiwara , Shumei Kato , Daisuke Nishizaki , Hirotaka Miyashita , Suzanna Lee , Mary K Nesline , Jeffrey M. Conroy , Paul DePietro , Sarabjot Pabla , Scott Michael Lippman , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2614)
DOI
10.1200/JCO.2023.41.16_suppl.2614
Abstract #
2614
Poster Bd #
456
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita
Poster
2022 ASCO Annual Meeting
Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
First Author: Annika Lenz
First Author: Radhika Gogoi